anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To obtain a food suitable for meals for medical care, baby foods, or foods for convalescent patients without separating and removing residual proteins by heat treating an enzyme hydrolysate in a soln. having a specified temp. and specified pH and further hydrolyzing. CONSTITUTION: (A) A whey starting material containing a whey protein such as a whey for the production of cheese or an acid whey produced by coagulation of casein with an acid producing enzyme is hydrolyzed with an enzyme. The obtd. hydrolysate is heat treated in a soln. having pH6 to 8, at 80 to 100 deg.C for 3 to 10min, and then cooled to 40 to 60 deg.C. (B) A protease (such as trypsin and chymotrypsin) is added to the obtd. material to hydrolyze the soln. above preferably for 60 to 180min. Then the material is heat treated, for example, at &gt;=75 deg.C to deactivate the enzyme. Thus, the objective food is obtd.
The isolation and characterization of cDNAs encoding poly(ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body&#39;s response to neoplastic disorder inducing agents and oxidative stress. Expression vectors containing the cDNAs and cells transformed with the vectors are described. Probes and primers that hybridize with the cDNAs are described. Expression of the cDNA in  E. coli  results in an enzymatically active protein of about 111 kDa and an active fragment of about 59 kDa. Methods for inhibiting PARG expression or overexpressing PARG in a subject for therapeutic benefit are described. Exemplary of PARG inhibitors are anti-sense oligonucleotides. The invention has implications for treatment of neoplastic disorder, heart attack, stroke, and neurodegenerative diseases. Methods for detecting a mutant PARG allele are also described. Antibodies immunoreactive with PARGs and fragments thereof are described.
1. A compound of formula (I):   in which R is residue of carboxylic acid having upto 18 carbon atoms. 2. A compound of formula (I) according to claim 1, in which R is acetyle. 3. A method for preparing compounds of formula (I) according to claim 1 or 2, wherein a compound of formula (II):   in which R has a value as defined hereinbefore is subjected to the action of sulfonic acid and then to a base selected from diazabicycloundecene, diazabicyclononene, 2,6-lutidine, 2,4,6-collidine or tetramethylguandine to obtain a compound of formula (III):   which is subjected to the action of carbonyldiimidazole, then to NH2NH2 hydrazine to obtain a corresponding compound of formula (I). 4. A compound of formula (III) according to claim 3 as intermediate products to obtain compounds of formula (I). 5. A compound of formula (III) according to claim 4, wherein R is acetyle. 6. A method for preparing compounds of formula (VIII):   wherein R&#39;1 is a hydrogen atom or a hydrocarbon radical having upto 23 carbon atoms, saturated or unsaturated, which can be interrupted by one or several heteroatoms and can carry one or several functional groups, wherein a compound of formula (I):   in which R is residue of carboxylic acid having ipto 18 carbon atoms is subjected to the action of an agent cleaving protected hydroxy groups to obtain a compound of formula (IV):   which is subjected to the action of aldehyde of formula (V):   in which R&#39;1 has a value as defined hereinbefore to obtain a compound of formula (VI):   which is subjected to the action of diimide in the presence of dimethylsulfoxide for hydroxyle oxidation in position 3, then to the action of an agent cleaving hydroxyle  in position 2&#39; to obtain a compound of formula (VII):   which is subjected to the action of a reducer to obtain a corresponding compound of formula (VIII), in which R&#39;1 is a radical.
&lt;P&gt;PROBLEM TO BE SOLVED: To generate a simulation model adapted to the situation of an operation, from a medical image.  &lt;P&gt;SOLUTION: Geometric information is acquired from the medical image to construct volume data of a required internal organ. The volume data is operated to form the position and attitude of the internal organ specified by an operator, into a position and an attitude adapted to the operation. A blood vessel model connected to the specified internal organ is generated according to the position and attitude of the specified internal organ. A fat model of predetermined thickness is imparted around the predetermined internal organ included in the volume data in the connected state of the blood vessel model, to generate volume data. The internal organ in the generated volume data is then meshed. A template model of predetermined shape is operated using a template and arranged around the generated blood vessel model. A segment model is generated based on the arranged template model.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing an enteric soft capsule enabling application of a rotary die method of forming capsules having various shapes and sizes and giving capsules having excellent enteric property and beautiful appearance by a simple process.  &lt;P&gt;SOLUTION: The method for producing the enteric soft capsule comprises a preparation step to prepare a capsule shell liquid containing gelatin, water, a plasticizer and 10-30 pts.wt. of a low-methoxy pectin having an esterification degree of 20-40% based on 100 pts.wt. of the gelatin, and a forming step to form the soft capsule containing a content filled in the capsule shell formed from the capsule shell liquid by a rotary die forming apparatus. A salt containing a polyvalent metal ion to gelatinize the low-methoxy pectin is not added to the capsule shell liquid in the production method, and the method is free from a step to immerse the formed soft capsule in a gelatinization liquid containing the polyvalent metal ion.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To achieve the cloning of DNA synthesis-inhibiting factors with functional assays.  &lt;P&gt;SOLUTION: An expression vector cDNA library derived from senescent cells has been used to isolate cDNA clones that encode DNA synthesis-inhibiting factors. Such inhibiting factors play a role in cellular senescence and aging and tumor formation. The present invention relates to the molecules, the inhibiting factors, antagonists, antisense nucleic acids against such the molecules and derivatives. The present invention relates to the diagnostic, therapeutic and in vitro uses of such the all medicinal ingredients.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To realize the quick and correct retrieval of a case history sheet file even if the number of digits becomes large by managing with retrieval by retrieving actually only higher order (N to n) digits even if a file number has N-digits. CONSTITUTION:Storage sections 11A to 11E, 12A to 12E are provided in accordance with the combinations of numerical values represented by the lower order n-digits of the file number of N-digits. These storage sections 11A to 11E, 12A to 12E are coordinated with the combinations of the numerical values represented by the lower m-digits in the higher order (N-n)-digits excluding the lower order n-digits of the N-digits file number, and are divided into storage areas 11aO to 11e9, 12a0 to 12e9. Then, they are displayed respectively by display means 11I, 12I on the basis of a file taking out request from the outsides. Here, N=2,3,...,n=1,2,...; n&lt;N, m=1,2,..., m&lt;=N-n. Thus, the case history sheet file can be quickly and correctly retrieved.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compounds for modulating protein kinase enzymatic activity.  &lt;P&gt;SOLUTION: The compounds for modulating protein kinase enzymatic activity for modulating cellular activity such as proliferation, differentiation, programmed cell death, migration and chemoinvasion are provided. More specifically, the compounds are quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in the cellular activity as the above. Compositions which contain these compounds and methods of using them to treat kinase-dependent diseases and conditions are also provided. Methods for producing the compounds and the compositions which contain these compounds are also provided.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention discloses Chinese herbal medicine oral liquid for treating diabetes and a production technology thereof. The production technology is characterized in that sterile Chinese herbal medicine powder is added into a liquid medium agreeable to the plant growth by use of biotechnology according to the modern medicine and traditional medicine theory and particularly according to the biomedicine theory winning a Nobel Prize and the nutrition of the medium is catalyzed into several times the content of medical components of the Chines herbal medicine through biochemical reactions so as to improve the curative effect of traditional Chinese medicine. In the traditional method of decocting the traditional Chinese medicine with water, less than 40% of the traditional Chinese medicine components are dissolved in water; in a more advanced method of traditional Chinese medicine fermentation, sweet water is converted into ethyl alcohol and multiple organic acids, and 90% of the traditional Chinese medicine components can be dissolved out; and both figures are lower than that of the technology adopted by the invention. The technology disclosed by the invention can be applied to all prescribed Chinese herbal medicines, which is an innovation based on successful culture of a single Chinese herbal medicine. The fructus lycii which is planted is harvested once per year, but the fructus lycii cultivated biologically is harvested once every 8-16 days. With the same principle, &#39;everything can be reaped after being sown&#39; in a culture tank, and factory-like agricultural production is realized.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new lactic bacterium strain having immunostimulating activity and gastric juice resistance, to provide an immunostimulating composition containing the new lactic bacterium strain, and to provide a food and drink and a medicine containing the immunostimulating composition.  &lt;P&gt;SOLUTION: The new lactic bacterium having the immunostimulating activity and the gastric juice resistance is lactic bacterium Pediococcus sp. KB1 (NITE P-755). The food and drink, the medicine and the like having the immunostimulating activity contain the lactic bacterium Pediococcus sp. KB1 (NITE P-755) as an active ingredient.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention relates to application of a traditional Chinese medicine in preparation of drugs for paranoid schizophrenia. The traditional Chinese medicine is prepared from the following active pharmaceutical ingredients in parts by weight: 10-16 parts of fructus psoraleae, 6-9 parts of asarum, 5-8 parts of peach kernel, 2-5 parts of fructus aurantii and 2-5 parts of fermented soybean. The invention adopts the pure natural traditional Chinese medicine raw materials, and the whole formula conforms to the &#39;monarch, minister, assistant and guide&#39; principle of traditional Chinese medicines. The clinical test for years proves that the medicine has favorable effects of activating blood circulation to dissipate blood stasis, promoting the circulation of qi and relieving the depressed liver, has definite curative effect on schizophrenia, and has the advantages of fewer types of drugs, low toxic or side effect and no obvious adverse reaction. The effective ingredients of the medicine can be easily released and quickly absorbed, and the drug effect can be easily displayed. The medicine is convenient to carry, easy to take and beneficial to large-scale production, and thus, is a safe and effective medicine.
PURPOSE:To obtain a pharmaceutical, stable to humidity and stabilized even by compression molding nicorandil useful as a remedy for angina pectoris into tablets, by blending nicorandil with an organic acid, saturated higher fatty acid which is a solid at ordinary temperature and saturated higher alcohol. CONSTITUTION:Nicorandil is blended with one or two or more organic acids (e.g. fumaric acid or oxalic acid) and one or two or more saturated higher fatty acids which are solids at ordinary temperature (e.g. palmitic acid or stearic acid) and/or one or two or more saturated higher alcohols which are solids at ordinary temperature (e.g. cetyl alcohol) and a pharmaceutical is prepared from the resultant blend by a conventional method to afford the aimed substance. The amounts of the added ingredients are based on the total weight of the pharmaceutical are &gt;=0.1wt.% organic acids and &gt;=0.5wt.% saturated higher fatty acids and saturated higher alcohols.
PURPOSE:A safe manicure agent, containing a silicone resin or silicone based copolymeric resin having oxygen permeability, having a specific oxygen gas permeability, capable of respiration of nails, and having improved beautiful appearance. CONSTITUTION:A manicure agent containing one or two of silicone resin or silicone based resin copolymeric resin, e.g. silicone-acrylic resin, having the oxygen permeability as main components and if necessary another resin, pigment, dyestuff, perfume or pearlescent agent, e.g. ethylene glycol distearate, and having 3X10&lt;10&gt; [cm&lt;3&gt;(STP)cm/cm&lt;2&gt;.sec.cmHg]. Nails are capable of respiring individually in place of the conventional nitrocellulose based lacquer, etc., and the deterioration, splitting and languidness of fingers after coating are prevented. A safe improved beautiful appearance is provided even after use for a long time.
PURPOSE:The titled composition usable for safe venoclysis, comprising IgM and a basic amino acid. CONSTITUTION:0.1-10pts.wt. basic amino acid (e.g., arginine, lysine, ornithine, histidine) is added to 1pt.wt. IgM to give an aqueous solution, to which a solubilizer, stabilizer, isotonic, agent, etc. are added. Or, it is further lyophilized, to give pharmaceutical preparation of IgM for venoclysis. When pharmaceutical preparation of IgM has &gt;=20wt% IgM based on total protein, it exhibits sufficiently characteristics as the pharmaceutical preparation of IgM. An IgM composition having &lt;=30% anticomplementary value at 2wt% solution is especially suitable as pharmaceutical preparation for venoclysis with low side effects. IgM is obtained by extracting the fraction III of Corn&#39;s ethanol fraction of human plasma with a solution of NaCl, etc., adding (NH4)2SO4, etc. to the extracted solution to precipitate an immunoglobulin fraction, centrifuging it to give a crude IgM fraction.
The invention discloses isoquinoline-1,3(2H, 4H)-diketone containing isobutyric acid dimethyl ester groups and a preparation method and application thereof. The compound has the structure shown in the formula (I). The preparation method includes the steps that N-methacrylyl-N-alkylbenzene formamide serves as a substrate, dimethyl 2,2&#39;-azobis(2-methylpropionate) serves as a free radical source, copper iodide serves as a catalyst, K3PO4 serves as alkali, DMF serves as a solvent, reaction is conducted in the air environment, reaction temperature is 90 DEG C, and the compound is obtained through column chromatography or thin-layer chromatography separation and purification after five hours of reaction. The compound shows a good inhibition effect on prostate cancer cells 22RV, some compounds obtained from the compound have good prospects in the aspect of prostatic cancer treatment, and a good opportunity is provided for fixing lead compounds for treating prostatic cancer. The synthesis reaction is easy to operate, a reaction system is mild, conditions are simple, cost is low, the yield is high, and the compound has great application and popularization value. Please see the formula (I) in the description.
PURPOSE:A cosmetic useful for the skin and hair, safe for human body and improved stability with time, obtained by blending a cosmetic component with an N-alkyl-amino sugar sugaralcohol or its salt. CONSTITUTION:A cosmetic component is blended with 0.001-30wt% N-alkyl- amino surgar sugaralcohol such as N-methyl-D-erythrosamine based on total amount of cosmetic. The cosmetic provides the skin with smoothness, wettness, softening effect on keratin, and improving effect on the skin, supplies hair with gloss, softness, raises makeup effect on hair and improves combing properties. The use of it together with an acid can provide pH buffering effect, emulsification improving effect, etc. When it is used as an alkalizing agent for a cold wave agent, its smell is much better than ammonia, etc. The N-alkyl-amino sugar sugaralcohol is obtained by reacting a saccharide of &gt;= tetrasaccharide with an alkylamine, followed by reduction.
A cosmetic process comprises applying cosmetic composition(s) on contact with keratin material under conditions for dissolution of polymer. The cosmetic composition(s) comprises water-soluble polymer(s), and compound(s) approved for food use made of layer(s) with matrix based on water-soluble polymer. Provided that when composition is formed from single layer with hydroxy propyl methylcellulose as sole water-soluble polymer, the composition eliminates glycerol with disodium salt of fuschin or with mixture of titanium dioxide and brown iron oxide. A cosmetic process for making up and/or caring for keratin material(s), comprises applying cosmetic composition(s) on contact with a keratin material under conditions for dissolution of the polymer. The cosmetic composition(s) comprises water-soluble polymer(s), and compound(s) approved for food use (&gt;=50 wt. %). The water-soluble polymer(s) is in the form of an anhydrous film. The compound(s) approved for food use is made of layer(s) containing a matrix based on water-soluble polymer. Provided that when the composition is formed from a single layer containing hydroxy propyl methylcellulose as sole water-soluble polymer, the composition does not also contain glycerol (28.5 wt.%) in combination with disodium salt of fuschin (28.5 wt.%), or glycerol (21 wt.%) in combination with mixture of titanium dioxide and brown iron oxide (7 wt.%). An independent claim is also included for cosmetic composition for making up and/or caring for the lips in the form of an anhydrous film; the cosmetic composition comprising compound(s) approved for food use (&gt;=50), particle(s) with a color and/or optical effect.
301,479. Fredriksson, P. E., and Blomberg, A. R. Dec. 1, 1927, [Convention date]. Void [Published under Sect. 91 of the Acts]. Light and other radiations, treating diseases with.-In radioactive compresses, bandages and the like, the radioactive substance, in finely divided state, is distributed throughout a fibrous carrier the fibres of which hold the substance and prevent the collection thereof into lumps- The fibrous substance mav be a wad of cotton wool in which case the wad is usually split lengthwise and the two halves reunited by pressure after radioactive substance has been distributed upon the inner sides of one or both halves, accompanied, if desired, by shaking or beating. The wad may be coated externally with glue or other adhesive through which, if not too dense, the radioactive substance may be introduced. The impregnated wad is enclosed in a covering of cloth leather or the like, or if no glue &amp;c. coating is provided, of oil-skin attached by sewing- Instead of cotton wool a wad of cloth of loose texture or formed with a fluffy nap as by teasing may be employed.
Lipid compositions and lipid compositions included in cosmetic products, personal care products, skin care products, nutraceuticals, bio fuels, bio-lubricants, oleo chemicals, nutritional products, other bio-products, and animal feed compositions. Concentrations of lipid components. A method of removing and recovering a lipid composition by mixing a lipid feedstock with a solvent, separating the mixture into a raffinate phase and an extract phase containing beneficial non-glyceride compounds, removing solvent from the extract phase and obtaining a concentrate phase, and recovering a lipid composition from the concentrate phase. A method of producing a fatty acid alkyl ester. A method of producing a distiller&#39;s product. A method of performing secondary extractions and recovering a lipid composition by performing a first extraction on a lipid feedstock, performing a second extraction on a lipid feedstock, and exploiting differences in solubility limits to create unique product fractions derived from naturally occurring lipids.
The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer&#39; disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by beta-amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.
PROBLEM TO BE SOLVED: To obtain the subject vaccine, especially useful for preventing Gumboro diseases and effective even in chicks as young as one-day old without any secondary effects by inserting a base sequence capable of encoding an antigen of an avian pathogen into an avian herpesvirus under specific conditions. SOLUTION: An avian herpesvirus prepared by inserting a base sequence capable of encoding and expressing an antigenic polypeptide of an avian pathogen into an UL43 gene under the control of a cytomegalovirus(CMV) immediate early(IE) promoter to provide a vector. Marek&#39;s disease virus, especially a herpesvirus of turkey is preferred as the vector. The base sequence is preferably inserted after deleting the UL43 gene. For example, a human HCMV IE promoter is used as the CMV immediate early promoter. A base sequence, etc., capable of encoding b VP2 polypeptide of Gumboro disease virus [infectious bursal disease virus (IBDV)] are preferred as the base sequence. A vaccine against the Gumboro disease is preferably administered in 10-10&lt;2&gt; PFU at a time.
The invention discloses an aurone compound, and a preparation method and application thereof. The aurone compound is extracted from aromatic tobacco, the 4&#39; site is acetyl, the structural formula is shown in the specification, and the aurone compound is named as 4&#39;-acetyl-5-hydroxy-6-methoxy aurone. The preparation method of the aurone compound comprises the following steps: treating raw materials, performing ultrasonic extraction, performing silica gel column chromatography, separating through high pressure liquid chromatography, and performing gel column chromatography. The aurone compound is applicable to the preparation of medicaments for resisting leukemia cells and/or human breast cancer cells. The aurone compound disclosed by the invention is separated out from aromatic tobacco for the first time, and the molecular formula and structure of the aurone compound can be confirmed. According to the invention, ethanol is used as solvent, thereby causing less environmental pollution, and ensuring high safety and environment friendliness; and the compound is simple in structure and easy to artificially synthesize. The compound has obvious inhibiting effect on leukemia cells (NB4) and human breast cancer cells (MCF7), and the IC50 values are respectively 2.6mu M and 1.8mu M, thus indicating that the aurone compound can be used as a lead compound of anticancer medicaments.